Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
British Journal of General Practice
Intended for Healthcare Professionals

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Editor’s Briefing

Do No Harm

Roger Jones
British Journal of General Practice 2017; 67 (656): 99. DOI: https://doi.org/10.3399/bjgp17X689425
Roger Jones
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

Published eLetters

eLetter submission guidelines

Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com. PLEASE NOTE: your email address will be published.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Jump to comment:

  • Gluten-free food prescriptions for children with coeliac disease: should families have to pay?
    Mark Tighe, Sarah Sleet, Sarah Currell, John Martin and John Puntis
    Published on: 11 June 2017
  • Do no harm - a serious concern
    Marion Brown
    Published on: 28 February 2017
  • Published on: (11 June 2017)
    Page navigation anchor for Gluten-free food prescriptions for children with coeliac disease: should families have to pay?
    Gluten-free food prescriptions for children with coeliac disease: should families have to pay?
    • Mark Tighe, Consultant Paediatrician, Poole Hospital
    • Other Contributors:
      • Sarah Sleet, Chief Executive, Coeliac UK
      • Sarah Currell, Paediatric Dietitian, Poole Hospital
      • John Martin, GP, Taunton
      • John Puntis, Consultant Paediatric Gastroenterologist
    The Department of Health is consulting (until 22nd June)1 on withdrawing gluten-free food (GFF) prescriptions for patients with coeliac disease (CD), aiming to save £25million. Many CCGs have already stopped or restricted prescribing, stating that families should buy their own GFF instead.

    CD affects 1% of the population, putting them at risk of long-term consequences (including subfertility, osteoporosis, lymphoma and poor growth), and the only treatment is a strict GF diet. Children are entitled to free NHS prescriptions, and dietary staples (bread, flour, pasta) have been available within regulated limits since the 1960's.2 Since ’gluten intolerance’ (functional symptoms exacerbated by gluten intake) emerged in the 1980’s, GFF is more evident in supermarkets but remains costly. Availability is poor in convenience and budget stores where low-income families and those without transport shop more frequently.3 One patient questionnaire found that 28% struggled to locate stores with GFF, and 27% reported difficulties identifying GFF.4

    In some CCG consultations, low-quality information reflects press reports claiming “thousands of prescriptions... for custard creams, doughnuts and pizzas”. Anything that prejudices adherence to a strict GF-diet has negative implications for long-term health and NHS resources, and NICE recommends access to GFF prescriptions.5 Natur...

    Show More
    The Department of Health is consulting (until 22nd June)1 on withdrawing gluten-free food (GFF) prescriptions for patients with coeliac disease (CD), aiming to save £25million. Many CCGs have already stopped or restricted prescribing, stating that families should buy their own GFF instead.

    CD affects 1% of the population, putting them at risk of long-term consequences (including subfertility, osteoporosis, lymphoma and poor growth), and the only treatment is a strict GF diet. Children are entitled to free NHS prescriptions, and dietary staples (bread, flour, pasta) have been available within regulated limits since the 1960's.2 Since ’gluten intolerance’ (functional symptoms exacerbated by gluten intake) emerged in the 1980’s, GFF is more evident in supermarkets but remains costly. Availability is poor in convenience and budget stores where low-income families and those without transport shop more frequently.3 One patient questionnaire found that 28% struggled to locate stores with GFF, and 27% reported difficulties identifying GFF.4

    In some CCG consultations, low-quality information reflects press reports claiming “thousands of prescriptions... for custard creams, doughnuts and pizzas”. Anything that prejudices adherence to a strict GF-diet has negative implications for long-term health and NHS resources, and NICE recommends access to GFF prescriptions.5 Natural alternatives, such as rice, are less nutritious, with 90% less iron and 82% less calcium than bread.6 In an era of rising health inequalities, protecting access to GFF on prescription at no cost to the family should remain a fundamental principle of care for children with CD. Innovative models for providing GFF and a national NHS procurement process could better reduce costs.

    References

    1. Department of Health.  Open consultation.  Availability of gluten-free foods on NHS prescription.  Published date: March 2017. www.gov.uk/government/consultations/availability-of-gluten-free-foods-on-nhs-prescription. 
    2. Coeliac UK. Campaign with us on prescriptions.  www.coeliac.org.uk/get-involved/campaign-with-us/campaign-for-us-on-prescriptions.
    3. Burden M, Mooney PD, Blanshard RJ, et al. Cost and availability of gluten-free food in the UK: in store and online. Postgrad Med J 2015;356:622-6
    4. Rashid M, Cranney A, Zarkadas M, et al. Celiac disease: evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics 2005; 1;116(6):e754-9.
    5. NICE Clinical knowledge summary. Coeliac disease. https://cks.nice.org.uk/coeliac-disease.
    6. O’Connor A. An overview of the role of bread in the UK diet. Nutr Bull 2012;356:193-212.

    Show Less
    Competing Interests: None declared.
  • Published on: (28 February 2017)
    Page navigation anchor for Do no harm - a serious concern
    Do no harm - a serious concern
    • Marion Brown, Psychotherapist and Mediator (Independent), .
    My concern is about what I think I am seeing happening around an apparent strong connection between ever rising prescribed medications (as a psychotherapist I have been looking particularly at antidepressants and other medicines prescribed for anxiety, insomnia etc.) and patients finding themselves with a 'working diagnosis' of 'medically unexplained symptoms' or somatic system disorders and treated as such.
     
    I would like to draw particular attention to the work of Fava and Carvalho et al:
    www.karger.com/Article/FullText/370338
    www.karger.com/Article/FullText/447034
     
    The wide-ranging multi-system side-effects, tolerance and withdrawal problems that have been seen with these commonly prescribed antidepressants (used both on- and off-label) - and which I hear many individual experiences of - seem to bear a startlingly close resemblance to the common 'medically unexplained symptoms'. I have been particularly alarmed to learn that the widely-used PHQ-9 and GAD-7 are used in conjunction with PHQ-15 to help in the 'diagnosis' of Medically Unexplained Symptoms - and that these questionnaires were developed in conjunction with Pfizer.
     
    We certainly need to be seriously exploring what physiological and psychological ha...
    Show More
    My concern is about what I think I am seeing happening around an apparent strong connection between ever rising prescribed medications (as a psychotherapist I have been looking particularly at antidepressants and other medicines prescribed for anxiety, insomnia etc.) and patients finding themselves with a 'working diagnosis' of 'medically unexplained symptoms' or somatic system disorders and treated as such.
     
    I would like to draw particular attention to the work of Fava and Carvalho et al:
    www.karger.com/Article/FullText/370338
    www.karger.com/Article/FullText/447034
     
    The wide-ranging multi-system side-effects, tolerance and withdrawal problems that have been seen with these commonly prescribed antidepressants (used both on- and off-label) - and which I hear many individual experiences of - seem to bear a startlingly close resemblance to the common 'medically unexplained symptoms'. I have been particularly alarmed to learn that the widely-used PHQ-9 and GAD-7 are used in conjunction with PHQ-15 to help in the 'diagnosis' of Medically Unexplained Symptoms - and that these questionnaires were developed in conjunction with Pfizer.
     
    We certainly need to be seriously exploring what physiological and psychological harm these so-called 'antidepressant' medicines may be causing, instead of continuing to view them as 'safe and effective'.
     
    I have detailed my own observations in my writing and further references – accessible at and via www.bmj.com/content/356/bmj.j268/rr-1
     
    I would also like to draw attention to James Davies' recent article:
    www.madinamerica.com/2017/02/sedated-society-prescribing-epidemic/
    and the TV interview about antidepressants to which he refers:
    www.bbc.co.uk/programmes/b08dnpkn#play
     
    Show Less
    Competing Interests: None declared.
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 67 (656)
British Journal of General Practice
Vol. 67, Issue 656
March 2017
  • Table of Contents
  • Index by author
Download PDF
Download PowerPoint
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do No Harm
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Do No Harm
Roger Jones
British Journal of General Practice 2017; 67 (656): 99. DOI: 10.3399/bjgp17X689425

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Do No Harm
Roger Jones
British Journal of General Practice 2017; 67 (656): 99. DOI: 10.3399/bjgp17X689425
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • REFERENCES
  • Figures & Data
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • The Extraordinary Challenge of Antimicrobial Resistance
  • Shock Therapy — Disaster Remodelling in the NHS
  • The Global Primary Care Crisis
Show more Editor’s Briefing

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242